Boston Scientific Inks Smart Therapeutics Deal, Closes On Radiotherapeutics
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to combine its GDC aneurysm coils with Smart Therapeutics, Inc.'s development-phase intracranial stent system to better treat intracranial aneurysmal disease under a definitive acquisition agreement, announced Dec. 13
You may also be interested in...
Boston Scientific
Purchase of German stent technology R&D firm Inflow Dynamics adds iridium oxide passive stent coating technology, which "may offer an attractive alternative for the segment of the international market that does not convert to a drug-eluting stent," the firm says. Clinical trials are ongoing. Announced Dec. 5, the deal also covers roughly 30 patents related to stent designs and coatings. Separately, Boston Scientific completes its purchase of neurovascular device maker Smart Therapeutics Dec. 3 (1"The Gray Sheet" Dec. 17, 2001, p. 23). Boston Scientific also is debuting its Maverick2 Monorail and Quantum Maverickcoronary balloon dilatation catheters in the U.S. The firm highlights the versatility and "pushability" of the low-profile Maverick2 and the Quantum Maverick's deliverable dilation force...
Boston Scientific
Purchase of German stent technology R&D firm Inflow Dynamics adds iridium oxide passive stent coating technology, which "may offer an attractive alternative for the segment of the international market that does not convert to a drug-eluting stent," the firm says. Clinical trials are ongoing. Announced Dec. 5, the deal also covers roughly 30 patents related to stent designs and coatings. Separately, Boston Scientific completes its purchase of neurovascular device maker Smart Therapeutics Dec. 3 (1"The Gray Sheet" Dec. 17, 2001, p. 23). Boston Scientific also is debuting its Maverick2 Monorail and Quantum Maverickcoronary balloon dilatation catheters in the U.S. The firm highlights the versatility and "pushability" of the low-profile Maverick2 and the Quantum Maverick's deliverable dilation force...
Boston Scientific
RadioTherapeutics acquisition announced Nov. 8 includes a radiofrequency ablation system for non-resectable liver lesions. Boston Scientific has distributed the system in the U.S. for radiological applications under a 1998 strategic alliance. Terms of the deal, set to close in December, were not disclosed...